Source comparison
BPC-157 Research Renal Considerations: Comparison
Acute ischemia-reperfusion (rat model) Protective—reduced tubular necrosis, preserved creatinine clearance NO-mediated vasodilation, reduced oxidative stress (SOD upregulation) Short-term exposure only (7–14 days), no chronic dosing data Suggests acute protect
This comparison does not assign a generated winner or score.
- Acute ischemia-reperfusion (rat model)
- Protective—reduced tubular necrosis, preserved creatinine clearance
- NO-mediated vasodilation, reduced oxidative stress (SOD upregulation)
- Short-term exposure only (7–14 days), no chronic dosing data
- Suggests acute protective effect but doesn't address long-term safety
- NSAID-induced nephrotoxicity (rat model)
- Protective—mitigated creatinine elevation, reduced BUN
- Restored renal blood flow independent of COX pathway
- Extrapolation to human NSAID users unclear, no PK data on interaction kinetics
- Most clinically relevant finding, but human dosing equivalence unknown
- Gentamicin-induced toxicity (rat model)
- Protective—reduced MDA, increased antioxidant enzyme activity
- Antioxidant mechanisms, reduced lipid peroxidation
- Aminoglycosides cause dose-dependent tubular toxicity—unclear if protection scales with injury severity
- Demonstrates antioxidant capacity but not mechanism specificity
- Human clinical use (research or off-label)
- No formal renal endpoint data published
- N/A—no controlled trials exist
- Zero human PK studies, no eGFR monitoring in cohorts, no long-term follow-up
- Critical gap—all safety inferences are preclinical extrapolations
- Chronic kidney disease models (none exist)
- Unknown
- Hypothesised angiogenic repair vs maladaptive fibrosis
- No animal models of CKD + BPC-157 published
- Absence of data in the most relevant clinical population